Characterization of ENU-induced mutations in red blood cell structural proteins by Kildey, K. et al.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Red blood cell transfusion remains an essential medical therapy 
for the treatment of a broad range of anaemias. Currently packed red 
blood cells (PRBCs) for clinical transfusion have a 42 day expiry 
post-collection. During storage red blood cells (RBC) undergo 
numerous biophysical and biochemical changes [1,2] (termed the 
storage lesion) that may alter the biological function of the transfused 
RBC and/or the immune response of patients post-transfusion. 
Clinical studies have reported an association between RBC storage 
and increased patient morbidity post-transfusion [3-5]. In addition, 
there is evidence of donor variability in the lifespan of RBCs in 
storage and onset of the storage lesion [6].  
There are two alternative approaches for investigation of 
association of the product of a genetic open reading frame to a 
phenotype, referred to as reverse and forward genetics. The “reverse 
genetic” approach investigates the function of a known gene by 
phenotypic analysis of cells or organisms in which the function of this  
  
 
 
 
 
 
 
 
 
gene is impaired [7]. In contrast, the “forward genetic” approach is a 
tool to identify modifications in cells or organisms through 
phenotypic analysis, then determine the genetic basis of an altered 
phenotype [8]. In this study, we have investigated both the forward 
and reverse approaches to study single nucleotide variation (SNV)-
based changes in proteins critical for RBC function that may impact 
on blood component storage and transfusion outcomes using the N-
ethyl-N-nitrosourea (ENU)-mutagenised murine model. 
ENU mutagenesis is a technique utilised to produce new 
pedigrees of mice with SNVs that facilitate investigation of protein 
function and disease states. ENU is a DNA-alkylating agent that 
introduces a high rate of random genome-wide SNVs into the mouse 
germline by affecting the spermatogonial (premeiotic) germ cells in 
the mice testes [9]. Importantly, the phenotypes from these point 
mutations more closely model human genetic variation than mouse 
transgenic models, as 70% of the disease causing alleles so far 
described in humans are the result of SNVs [10]. SNVs are more 
likely to result in inactive or altered function of a particular domain of 
a protein, highlighting active sites or functions of variant forms of the 
protein. ENU-mutagenised mice are available for selection from a 
number of libraries for investigation of a defined gene mutation 
(reverse genetics). In addition new gene function and potential disease 
association can be discovered by screening ENU pedigrees for 
phenotypes of interest (forward genetics).  
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Mature human RBC’s have a biconcave discoid shape and can 
survive shearing stress and undergo elastic deformation to allow 
passage through capillaries. The elastic filamentous RBC cytoskeleton 
is composed of four major interconnected components: spectrin1-α 
(240 kDa), spectrin1-β (220 kDa), band 4.1 (80 kDa) and actin (β-
type; 42 kDa), which are the basis of the RBC’s structure and 
mechanical properties [11]. The RBC cytoskeletal proteins are 
attached to the plasma membrane through interaction with ankyrin 
and transmembrane protein band 3 that is embedded in the lipid 
bilayer [12-14]. Disruptions to these protein interactions have been 
associated with genetically-inherited RBC-related diseases in human 
populations including hereditary spherocytosis (HS), elliptocytosis, 
stomatocytosis and pyropoikilocytosis [15-17]. In addition to effects 
on RBC morphology and structural integrity, disruptions in RBC 
cytoskeletal proteins have been reported to impact on RBC survival 
and/or differentiation [18,19]. Human and murine RBCs share a 
similar cytoskeletal structure [20], though they differ somewhat in 
lifespan (human RBC predicted 120 days, murine RBC estimated 50 
days) in circulation [21]. Murine RBC have been used to model 
human RBC-related disease [22-24] and provide a suitable platform 
to study genetic changes in RBCs that may impact on the structural 
integrity, differentiation and survival of RBCs and therefore 
component storage and transfusion outcomes. 
In this study, we have used murine ENU-mutated models, using 
both the forward and reverse genetic approaches, to investigate the 
effect of SNV-based changes on RBC. Pedigrees with SNVs in 
Epb4.1 (encoding band 4.1), and three different SNVs in Spnb-1 
(encoding spectrin-1β), selected for the reverse genetic approach, 
demonstrated some perturbation of haematological parameters. In 
contrast, the forward genetic approach resulted in the generation of a 
pedigree characterised by reticulocytosis, microcytic anaemia and 
thrombocytosis. This phenotype was determined to be the result of a 
novel mutation in Ank1, encoding the RBC structural protein 
ankyrin-1.  
 
Experimental procedures 
 
ENU-mutagenesis was performed on C57BL/6 mice by the 
Australian Phenomics Facility (Australian National University 
(ANU) Canberra) [9,25]. Briefly, male C57BL/6 mice were treated 
with three intraperitoneal injections of 80 µg ENU/gram of body 
weight. Ten weeks post mutagenesis ENU-treated males were crossed 
with multiple female C57BL/6 mice to produce pedigrees with 
randomly incorporated point mutations. ENU-pedigrees on a 
C57BL/6 genetic background were produced using a three generation 
approach to reveal recessive mutations [9]. To reduce the mutation 
load in the resultant pedigrees G1 mice were crossed with background 
C57BL/6 mice, and G2 siblings mated (or G2 backcrossed to G1) to 
generate homozygous G3 mice. Mice were maintained at the 
Australian Phenomics Facility, Canberra. Animal protocols were 
reviewed and approved by the Australian National University 
experimentation ethics committee, and all procedures were carried out 
under the guidelines of the Australian code of practice for the care 
and use of animals for scientific purposes. 
ENU-induced Mutations in RBC Structural Proteins 
2 
Volume No: 6, Issue: 7, e201303012 Computational and Structural Biotechnology Journal | www.csbj.org 
Using a forward genetics approach an ENU-induced mutant 
pedigree was selected for further breeding and analysis based on an 
identifiable phenotype. Briefly, using a "homozygote recessive" 
breeding strategy, blood from 33 ENU-induced mutant pedigrees was 
screened for evidence of a changed blood picture by a differential cell 
count (RBC, platelet, white blood cell (WBC), neutrophil, 
lymphocyte, monocyte, eosinophil, basophil, and reticulocytes) and 
measurement of standard haematological parameters (Hb, HCT, and 
mean corpuscular volume (MCV)) undertaken using an ADVIA 
analyser (Siemens Healthcare Global). Mice with altered 
haematological parameters were selectively bred. Causative mutations 
were identified via exome sequencing (G4 mice). Where indicated 
mice were sacrificed, spleens excised and measured (wet weight (g), 
length (cm)). 
 
Based on the presence of ENU-induced mutation in RBC 
structural proteins, four pedigrees were selected from the Australian 
Phenomics Facility missense mutation library [26]. Three pedigrees, 
each with different SNV in Spnb1 (encoding spectrin-1β), and one 
pedigree with a SNV in Epb4.1 (encoding band 4.1) were selected 
for assessment in a “reverse genetics” approach to investigate factors 
that may alter RBC integrity (Table 1). Homozygous pedigrees for 
the Epb4.1 SNV and the three individual Spnb1 SNVs were 
generated from G2 heterozygous mice using genetic screening. All 
genomic positions of the mutations were referenced to the Genome 
Reference Consortium Mouse Build 38 (GRCm38). 
 
ENU variations were identified via exome sequencing as 
previously described [25]. Briefly, exome enriched, paired end libraries 
were prepared from genomic DNA of each sample. The Illumina 
paired-end genomic DNA sample preparation kit (PE-102-1001, 
Illumina) was used for preparing the libraries including end repair, A-
tailing and ligation of the Illumina adaptors. Nimblegen SeqCap baits 
(#999042611, Roche Diagnostics) designed to 203,225 exons and 
54Mb of the reference coding regions were used to enrich for the 
mouse exome. Each sample was prepared with an index using the 
Illumina multiplexing sample preparation oligonucleotide kit (PE-
400-1001, Illumina) and then pooled in batches of four in equimolar 
amounts prior to capture. Each capture was sequenced in a single lane 
of a HiSeq 2000 (Illumina) as 100bp paired end libraries. Sequence 
reads were mapped to the mouse reference assembly and SNVs 
identified and annotated [23]. 
 
Primers were designed using Amplifluor™ Assay Architect™ on-
line design program (Table 2). Multiplexed PCR was performed in 
96 well plates on Eppendorf MasterCycler ProS thermocycler 
(POCD Pty Ltd, Artarmon, NSW). Genomic DNA (gDNA) was 
obtained from 2-3 mm ear punch. Sample was prepared by adding the 
ear tissue to 15 µl of TE-Tween Lysis buffer (50 mM Tris HCl, pH 
8.0, 0.125 mM EDTA, 2% Tween 20) and sample centrifuged (2 
min, 2500 g). The prepared tissue sample was digested in 15 µl ear 
punch digestion mix (14 µl TE-Tween Lysis Buffer, 1.0 µl Proteinase 
K (20 mg/ml)), by incubating at 55°C for 1 hour, followed by 99°C 
for 10 min to denature the proteinase K. Samples were centrifuged 
(10 min, 2500 g) and washed with 180 µl of sterile ddH2O.  
PCR was performed in a 5 µl reaction containing 1 µl of gDNA, 
0.1 µM PCR Amplifluor primer mix, 0.25 µM amplifluor universal 
FAM Primer (IDT), 0.25 µM amplifluor universal JOE Primer 
(IDT), 0.2 mM dNTPs each, 10x Taq DNA Polymerase PCR buffer 
(Invitrogen), 1.8 mM MgCl2, and 0.05 units of MyTaq™ HS DNA 
Polymerase. PCR cycling conditions were 95ºC for 4 min, followed 
by 35 cycles of 95ºC for 10s, 60ºC for 20s and 72ºC for 10s followed 
by a final elongation of 72ºC for 3 min. 
 
To further annotate the SNVs bioinformatics modelling was 
utilised to evaluate and predict the functional significance of 
mutations for each pedigree. A polymorphism phenotyping 
computational tool (PolyPhen-2) predicting potential impact of 
amino acid substitutions on the structure and function of the protein 
(8 sequence based and 3 structure based) was utilised [24]. The 
Polyphen-2 software was adjusted to more accurately predict the 
damaging effect of SNVs in the mouse genome [23]. PolyPhen score 
and predictive disruption indicated in Table 1.  
E5M binds to band 3 and Rh-related proteins on RBCs and is 
utilised as a tool to assess changes in RBC surface area. E5M staining 
was based on a previously published assay [27]. Briefly, 0.5 mg/ml 
E5M was prepared in PBS. Ten microliters E5M (0.5 mg/ml) was 
mixed with 5μL of pre-washed murine RBC (PBS pH 7.4) and 
incubated (room temperature (RT), dark, 1 hour) with intermittent 
mixing. RBCs were washed thrice with 500 μl PBS. On final wash the 
cell pellet was resuspended in 500 μl PBS. The labelled cell 
suspension was further diluted 1:10 in PBS for analysis via flow 
cytometry (BD FACSCanto II, 3 laser flow cytometer, BD 
Biosciences, USA).  
 
Differences in the osmotic fragility of murine RBC were evaluated 
by lysis in hypotonic saline, based on a previously published assay 
with some minor modifications [28]. Briefly, eleven hypotonic-saline 
solutions (0.9, 0.8, 0.75, 0.7, 0.65, 0.6, 0.55, 0.5, 0.45, 0.4, and 
0.3% NaCl respectively) were prepared in milli-Q H2O. In a v-
bottom 96 well microtitre plate, 2 µl of murine whole blood 
(representing approx. 2x107 cells) was added followed by 200 µl of 
each saline solution or H2O (100% lysis control), and incubated (30 
min, RT). After incubation, plates were centrifuged (1000xg, 5 min) 
and 100 µl of the supernatant was transferred to a fresh 96 well flat 
bottom microtitre plate. Haemolysis was measured at 450nm. 
 
 Murine plasma was incubated with analyte-specific bead populations, 
and bound cytokine and chemokine analytes were detected with PE-
conjugated antibody. Inflammatory mediators interleukin-6 (IL-6) 
and RANTES (CCL5), were quantified using Becton Dickenson 
(BD) CBA (BD Biosciences, Australia) according to the 
manufacturer’s instructions with minor modifications [29]. In brief, 
plasma was diluted 1:4 and incubated with 0.5μL of each capture 
bead for 1hr; 0.5μL of each detection reagent was then added and 
incubated for a further 2hr and analysed on a BD FACSCanto II (BD 
Biosciences, Australia). FACSArray software (BD Biosciences, CA, 
USA) was used for analysis to quantify concentrations from the 
standard curves run in parallel. Standard curves for IL-6 and 
RANTES assays ranged from 10-2500 pg/ml. 
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Where indicated, levels of erythropoietin (EPO) and 
thrombopoietin (TPO) were assessed via ELISA according to 
manufactures instructions (MEP00B, MTP00; R&D systems, USA). 
Briefly, plasma was diluted 1:2 (TPO) or 1:5 (EPO) in respective 
assay diluents and incubated for 2hrs. Plates were washed and 
respective conjugate antibody added for 2hrs. Plates were washed 
before addition of substrate for 30min and reaction stopped with 
diluted hydrochloric acid. Absorbance measured at 450nm (540nm 
reference).  
 
Unpaired data was compared using a t-test. One-Way Analysis of 
Variance (ANOVA) was performed where indicated. GraphPad 
Prism (V) was used for all statistical analysis with 95% CI 
(GraphPad Software, La Jolla, USA). 
 
Results 
 
For the forward genetic approach, 33 ENU-induced mutant 
pedigrees were screened for evidence of a changed blood picture. 
Screening resulted in identification of a subset of mice with an 
affected phenotype characterised by a significant elevation in 
reticulocyte count (p<0.0001 unpaired T-test affected cf. unaffected 
mice; Figure 1A). The affected mice were chosen for further breeding 
and analysis.  
 
Exome sequencing of G4 affected mice identified a SNV in Ank1 
(encoding RBC structural protein ankyrin-1) as a candidate ENU-
induced mutation resulting in the high reticulocyte phenotype. 
Sequencing revealed a G→A substitution on Chromosome 8 (base 
pair position 23,119,434: GRCm38); the first base of the splice 
donor site 5’ of Ank1 exon 34. The Ank1 mutation was predicted to 
result in a splice variant of ankyrin-1 with a potential loss of the 
amino acids encoded for by exon 34 (Figure 1B). Ankyrin-1 is an 
erythrocyte cytoskeletal protein that provides a link between RBC 
membrane structural proteins (spectrin and band 3) and the inner 
surface of the lipid bilayer [14,30]. The mutation reported here is 
different from previously reported Ank1 mutations in both humans 
[15,31] and mice [19,32-34]. Defects in ankyrin-1 have been found 
in >50% of cases of HS in humans, characterised by evidence of 
haemolysis with anaemia, spherocytic RBC, reticulocytosis, jaundice, 
gallstones and splenomegaly [35]. This novel ankyrin pedigree may 
model some forms of human HS and is a valuable tool for further 
characterisation of this disease. The pedigree was designated Ank1EX34.  
 
β
In a reverse genetics approach, four ENU pedigrees with SNV in 
genes encoding RBC structural proteins (band 4.1 and three 
individual spectrin-1β (designated a, b, c)) were selected from the 
Australian Phenomics Facility missense mutation library [26]. 
Together with the novel Ank1EX34 pedigree differential cell counts and 
standard haematological parameters were assessed (Table 3). In 
homozygous Ank1EX34 mice, the significantly elevated reticulocyte 
count was consistently observed (p<0.0001), and was compounded 
with significantly decreased RBC count (p<0.0001), Hb 
(p<0.0001), HCT (p<0.0001), and MCV (p<0.0001). In addition, 
homozygous Ank1EX34 mice exhibited thrombocytosis as evidenced by 
significantly elevated platelet count (p<0.0001: Table 3). Mice 
heterozygous for the Ank1 mutation also showed a significantly 
increased reticulocyte count (p=0.0026) and reduced MCV 
(p=0.0114; Table 3).  
While mutation in Ank1 predominantly resulted in reduction of 
key RBC parameters indicating a disruption in RBC structural 
integrity, SNV in Spnb1 (a) and Spnb1 (b) resulted in elevated RBC 
parameters. In mice carrying homozygous Spnb1 (a) or Spnb1 (b) 
mutation, significantly increased RBC count (p=0.0211 (a), 
p=0.0476 (b)), haemoglobin (p=0.0253 (a), p=0.0432 (b)), and 
HCT (p=0.0186 (a), p=0.0431 (b)) was evident (Table 3). With 
the exception of a significantly increased MCV (P=0.0285) in 
heterozygous Spnb1 (b) mice, these altered blood parameters were not 
evident in the heterozygous Spnb1 (a) or (b) mice.  
Figure 1. Identification of novel high reticulocyte ENU phenotype and identification of causative mutation. A) G2 ENU treated mice were screened for key 
haematological parameters. A phenotype characterised by high reticulocyte was identified (*** p<0.0001 affected cf. unaffected). Affected mice were selected 
for further breeding and analysis. B) Schematic representation of the position of the ENU-induced mutation in Ank1. Sequencing revealed the phenotype was a 
result of a novel splice variant in Ank1, specifically a G  A substitution at the first base of the donor splice site for exon 34. 
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SNV in Spnb1 (c) or Epb4.1 did not significantly affect the 
haematological phenotype, as there was no significant difference 
between the blood picture in either homozygous or heterozygous mice 
with these mutations compared to their unaffected siblings (Table 3). 
Of note, the MCV and HCT was reduced in all mice studied from 
the band 4.1 pedigree, regardless of the carriage of Epb4.1 mutation 
(unaffected, heterozygous or homozygous) and it is hypothesised that 
another causative mutation was responsible for the reduced red cell 
size in this pedigree.  
 
Standard osmotic fragility testing was performed on red cells from 
all pedigrees to investigate potential changes in RBC structural 
integrity. Homozygous Ank1EX34 mice demonstrated significantly 
increased osmotic fragility (Figure 2A). There was no significant 
difference in the osmotic fragility of RBCs from mice from pedigrees 
either homozygous or heterozygous for the Epb4.1 or any of the 
Spnb1 mutations (Figure 2B-E).  
 
E5M binds to band 3 (at lysine 430) and Rh-related proteins on 
RBC membranes; a reduction in E5M staining indicates a disruption 
in the RBC cytoskeleton [36]. A clinical diagnosis of HS is associated 
with reduced E5M binding to the RBC membrane [27,36-38]. As 
expected the Ank1EX34 pedigree demonstrated significantly reduced 
E5M binding (Figure 3A). This reduction was evident in both 
heterozygous and homozygous mice, though the effect was more 
pronounced in the homozygous mice as indicated by fluorescent 
intensity (Figure 4A). There was no difference in E5M staining of 
RBCs from the spectrin-1β (a), spectrin-1β (b), spectrin-1β (c), or 
band 4.1 pedigrees (Figure 3 B-E, Figure 4 B-C).  
Figure 2. Osmotic fragility of RBC from ENU pedigrees. A) RBC from the ANK-1EX34 pedigree (ankyrin-1) had increased osmotic fragility (ANOVA p<0.0001). 
Homozygous ANK-1EX34 had increased osmotic fragility compared to both the background and heterozygous mice (p<0.001, p<0.05 respectively; Tukey post-
test). B-E) No difference in RBC osmotic fragility for band 4.1 or any of the spectrin-1β pedigrees.        
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Damaged or atypical RBCs are sequestered in the spleen and 
removed from circulation. Splenomegaly is a common feature in 
humans with HS and splenectomy is sometimes required [35]. 
Ank1EX34 mice were sacrificed and spleens excised to investigate 
abnormal RBC clearance. As expected, spleens from homozygous 
Ank1EX34 mice were enlarged, consistent with sequestration of 
abnormal RBC and/or increased RBC turnover (Figure 5). Increased 
RBC turnover and associated splenomegaly may lead to an 
inflammatory response. IL-6 and CCL5 (RANTES) were quantified 
in plasma of Ank1EX34 mice as an indication of inflammation. IL-6 
was not detected in any of the samples assayed and there was no 
change in levels of CCL5 attributed to Ank1 mutation (data not 
shown). EPO and TPO are key growth factors involved in RBC and 
platelet differentiation and haemostasis. EPO is a glycoprotein 
hormone that signals to increase RBC turnover and expression is 
increased in hypoxic conditions [39]. EPO levels were significantly 
increased in homozygous Ank1EX34 mice compared to heterozygotes 
and unaffected siblings (p=0.021, p=0.001 respectively, Figure 6A). 
Heterozygous Ank1EX34 mice also had significantly elevated EPO 
levels compared to unaffected siblings (p=0.004, Figure 6A). TPO is 
a humoral growth factor that is necessary for megakaryocyte 
proliferation and maturation, as well as for thrombopoiesis [40]. 
Homozygous Ank1EX34 mice had significantly reduced TPO levels 
compared to unaffected siblings (p=0.04, Figure 6B). The reduction 
in circulating TPO in homozygous Ank1EX34 mice is likely due to 
depletion via c-Mpl receptor binding consistent with the elevated 
platelet count in this pedigree.  
 
Discussion 
 
Murine RBCs provide a suitable platform to study genetically 
defined changes in RBCs that may impact on structural integrity, 
differentiation and lifespan. These features are central to RBC 
Figure 3. Representative histograms of E5M flow cytometric analysis of RBC integrity. Grey solid peaks indicate E5M on RBC from C57/B6 background mice, 
black solid line indicates homozygote RBC and dashed line heterozygote RBC. A) Ank1EX34 (Ankyrin-1) homozygotes displayed reduced E5M staining and 
heterozygotes an intermediate reduction in E5M staining. B-E) No differences observed in the band 4.1 or spectrin-1β pedigrees. 
Figure 4. Median fluorescent intensity (MFI) of E5M staining of RBC from 
ENU-pedigrees. A) Ank1EX34
 
(Ankyrin-1) MFI was reduced in both the 
homozygotes (HOM) (p<0.0001) and heterozygotes (HET) (p<0.001) cf. 
C57/B6 background pedigree. No difference in RBC integrity was observed 
for B) band 4.1 or C) spectrin-1β pedigrees.  
 
# ANOVA; **p<0.01, *** p<0.001, Tukeys post-test. 
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functionality and any changes or disruption in RBC parameters may 
impact on the storage capacity of the blood component, and further 
may result in poor patient outcomes post-transfusion. Post-collection 
packed red blood cells are stored for up to 42 days before transfusion. 
Clinical studies have reported an association between RBC storage 
and increased patient morbidity post-transfusion [3-5], and there is 
evidence of donor variability in the lifespan of RBC in storage and 
onset of the storage lesion [6]. In this study, we used murine ENU 
models with both forward and reverse genetic approaches to study 
genetic-based changes in RBC parameters that may have important 
implications for storage of blood components for clinical use and 
transfusion outcomes in humans.  
 
 
 
 
 
 
 
For the reverse genetics approach ENU pedigrees were chosen for 
investigation based on mutation in RBC structural proteins. At the 
commencement of the study, there were four defined mutations in 
genes encoding RBC structural proteins available for study; one 
mutation in Epb4.1 (encoding band 4.1) and three separate mutations 
in Spnb1 (encoding spectrin-1β). Band 4.1 and spectrin-1β are 
functionally important RBC cytoskeleton proteins. Band 4.1 
associates with a number of RBC structural proteins including 
spectrin, actin, adducin, dematin, tropomodulin, tropomyosin, band 3 
and glycophorin C in the 4.1R complex which spans the lipid bilayer 
[41]. Spectrin-1β is an intracellular self-assembling protein that in 
association with spectrin-1α forms an anchoring point for the band 3 
and band 4.1R complexes. Thus both band 4.1 and spectrin-1β are 
key structural proteins that contribute to the stability and elasticity of 
the RBC. Mutations in these proteins have the potential to affect 
RBC structural integrity, differentiation and survival.  
All of the SNVs studied in the spectrin-1β pedigrees occurred in 
the region encoding the spectrin-binding domain of the protein. It is 
not surprising that ENU mutagenesis would result in a number of 
mutations in this region as a large portion of Spnb1 encodes the 
spectrin-binding domain. Of the three Spnb1 SNVs studied, 
Spnb1(c) had the highest prediction of loss of function based on 
bioinformatic modelling. However, this mutation had the least impact 
of the three Spnb1 mutations studied, with the pedigree exhibiting no 
evidence of altered haematological profile, and no difference in RBC 
structural integrity in terms of osmotic fragility or E5M binding. The 
spectrin-1β (a) and (b) pedigrees were both characterised by 
significantly increased RBC count, Hb and HCT, despite the low 
PolyPhen score and prediction of a benign mutation. Although there 
were increases in the RBC count (and associated Hb and MCV) in 
the spectrin-1β (a) and (b) pedigrees, the RBC did not appear to have 
altered structural integrity as no changes were apparent in osmotic 
fragility or E5M binding.  
The SNV in Epb4.1 results in a ThrAla amino acid 
substitution in the hydrophilic domain of the encoded band 4.1 
protein and bioinformatic modelling determined this mutation was 
“probably damaging”. Despite the PolyPhen score and predicted 
disruption, we saw no evidence of changed blood picture due to 
mutation in Epb4.1. We observed a consistently reduced MCV and 
HCT in this pedigree, regardless of the presence or absence of the 
defined mutation in Epb4.1. ENU mutagenesis results in multiple 
mutations in the murine germ line and the reduced MCV and HCT is 
likely the result of a dominant mutation in another gene. 
Retrospectively, we assessed the other mutations reported to be 
present in the band 4.1 pedigree. There were 46 other SNV identified 
and the majority of the mutations were in genes primarily associated 
with cancer, cell cycle/survival and development and cardiovascular 
disease.  
 
A) 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
Of the 46 additional SNVs in the band 4.1 pedigree, on the basis 
of currently described function, mutations in Trank1, E2f8, Etnk2 
and Yars2 will be the first investigated to determine if these 
mutations are associated with the reduced MCV and HCT in this 
pedigree. Trank1 encodes tetratricopeptide repeat and ankyrin repeat-
containing protein 1, a protein predicted to contain multiple ankyrin 
repeat domains. To date, there are limited reports on the function of 
Figure 5. Excised spleens from Ank1EX34 pedigree. A) Spleen of unaffected 
Ank1EX34 sibling. B & C) Spleens from Ank1EX34 homozygotes. Weights of 
spleens indicated in grams (g). 
 
Figure 6. Modulation of RBC and platelet growth factors in Ank1EX34 
pedigree. A) RBC growth hormone EPO was significantly increased in both 
heterozygous (HET) and homozygous (HOM) Ank1EX34 mice. B) 
Megakaryocyte growth factor TPO was significantly decreased Ank1EX34 
homozygote mice. *p<0.05 ** p< 0.01 unpaired T-test cf. unaffected 
(UNAF). 
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this gene product, however, the presence of numerous ankyrin repeats 
and predicted “probably damaging” PolyPhen score as a result of a 
PheLeu amino acid substitution suggests SNV in Trank1 has the 
potential to impact on RBC structural integrity. E2f8 encodes E2f 
transcription factor 8. This transcription factor is also not well 
described however putative roles in cell cycle, endocycle and placental 
development have been reported [42]. Dysfunction in E2f8 has been 
linked to anaemia [43]. The mutation in E2f8 is predicted to be 
“possibly damaging” as a result of SerIle amino acid substitution. 
Mutations in Etnk2 and Yars2 were also predicted to be “possibly 
damaging”. Etnk2 encodes ethanolamine kinase 2, a member of the 
choline/ethanolamine kinase family. This enzyme catalyses the first 
step of phophatidylethanolamine biosynthesis and deficiency has been 
associated with altered haematologic parameters in mice [44]. Yars2 
encodes tyrosyl-tRNA synthetase 2, a mitochondrial protein that 
catalyses the attachment of tyrosine to tRNA. Mutations in this gene 
are associated with myopathy, lactic acidosis and sideroblastic anaemia 
type 2 [45]. Based on the presentation of the phenotype in all band 
4.1 mice regardless of Epb4.1 SNV carriage, we hypothesise an 
autosomal-dominant inheritance and matings for this pedigree are 
being designed to assist in the analysis of the causative mutation.  
Using the forward genetic approach a novel ENU-mutant 
pedigree with an elevated reticulocyte count was identified. Further 
analysis revealed reduced Hb and lower MCV. Sequencing revealed a 
G→A substitution on Chromosome 8 (base pair position 
23,119,434: GRCm38); the first base of the splice donor site 5’ of 
Ank1 exon 34. The Ank1 SNV occurs in a splice site motif in 
ankyrin-1 likely to be associated with loss of the exon 34 amino acid 
sequence. Ankyrin-1 is an erythrocyte cytoskeletal protein that 
provides a link between RBC membrane structural proteins (spectrin 
and band 3) and the inner surface of the lipid bilayer [14,30]. 
Mutations in Ank1 have been associated with hereditary spherocytosis 
(HS), an inherited haemolytic anaemia characterised by rigid spheroid 
RBCs [35]. Patients with spherocytosis exhibit anaemia with a 
compensatory reticulocytosis as a result of haemolysis of spherocytic 
red cells, jaundice, gallstones and splenomegaly [35].  
The Ank1 SNV reported in this study was different to previously 
reported Ank1 mutations in both humans [15,31] and mice [19,32-
34], although the phenotypes were similar. The Ank1EX34 pedigree 
characterised in this study demonstrates elevated reticulocyte count, 
reduced Hb, lower MCV, splenomegaly, reduced RBC E5M staining 
and increased RBC fragility, all of which are characteristic of HS. The 
Ank1EX34 pedigree also exhibited thrombocytosis, a characteristic not 
commonly associated with Ank1 mutation or HS. Ank1 mutations 
have also been associated with increased malarial resistance in a 
number of murine studies [34], and human HS as a result of Ank1 
mutation may be the result of evolution to prevent malarial infection. 
While malarial resistance was not the focus of our study, it is a 
reasonable hypothesis that the Ank1EX34 pedigree would demonstrate a 
resistance to malarial infection.  
To further characterise this novel Ank1EX34 pedigree, we also 
studied potential changes in inflammation and modulation of RBC 
and platelet growth factors. Despite an altered haematological 
phenotype and splenomegaly in the Ank1EX34 pedigree, we did not 
find evidence of changes in the inflammatory mediators we studied. 
IL-6 is a pro-inflammatory cytokine, primarily synthesised by the 
liver. IL-6 is a pleiotropic cytokine with key roles in infection, 
inflammation, autoimmunity and tissue haemostasis [46]. IL-6 levels 
were at the limit of detection (<10pg/ml) in the Ank1EX34 pedigree, 
despite the clear dysfunction in a number of key biological systems in 
these mice. We also studied EPO and TPO as two key cytokines that 
contribute to RBC and platelet differentiation and haemostasis. EPO 
was significantly increased in both heterozygous and homozygous 
Ank1EX34 mice. EPO synthesis is increased in response to hypoxia and 
signals erythroid progenitor cells to differentiate into erythroblasts 
[39]. As the Ank1EX344 pedigree was defined in the first instance by an 
elevated reticulocyte count, it was not surprising that a significantly 
elevated EPO was associated with this phenotype. TPO is a humoral 
growth factor that is necessary for megakaryocyte proliferation and 
maturation, as well as for thrombopoiesis [40]. We observed 
significantly reduced TPO in homozygous Ank1EX34 mice. As these 
mice also exhibit thrombocytosis, it is likely the reduction in 
circulating TPO is due to depletion via c-Mpl receptor binding on 
platelets, though other mechanisms may also contribute to the TPO 
feedback loop, as high platelet count does not always correlate with 
reduced levels of TPO in the circulation [47,48]. 
Using murine genetic models derived by ENU mutagenesis, RBC 
structural proteins were characterised in five pedigrees. Using a 
forward genetic screening approach we identified a phenotype 
characterised by reticulocytosis, microcytic anaemia and 
thrombocytosis. This phenotype was determined to be associated with 
a novel mutation in Ank1, encoding the RBC structural protein 
ankyrin-1. The forward approach was therefore a useful tool to 
identify and characterise the genetic basis of an altered haematological 
phenotype. As the Ank1EX34 mutation is in a splice motif, there is no 
PolyPhen score associated with this SNV. Four pedigrees were 
investigated from a reverse genetics approach, to identify a phenotype 
associated with the presence of a known mutation. For the SNVs 
studied we found the PolyPhen score was not correlated with a 
changed phenotype for any of the assays employed. There was no 
evidence of altered haematological parameters or RBC structural 
integrity resulting from the two SNVs that were predicted to result in 
a damaging phenotype (Spnb1(c) and Epb4.1). These mutations may 
be damaging, however altered phenotype may not have been evident 
due to molecular redundancy. The two SNVs predicted to be benign 
(Spnb1 (a) and (b)) demonstrated an increased RBC count, HCT and 
Hb. Our findings suggest that new generations of bioinformatic 
prediction tools used in concert with feedback from phenotypic 
analysis will improve capacity to predict altered function. 
This study was established in the context of understanding factors 
that may influence the outcomes of blood transfusion. The 
haemoglobin increment following transfusion is highly variable and 
there are minimal studies of non-serological variables associated with 
differences in post-transfusion survival of RBC. In this study we 
targeted SNVs in genes encoding proteins critical for RBC function 
that are expected to be important in post-transfusion RBC survival. 
The Ank1 mutation is clearly associated with anaemia and elevated 
RBC turnover. The impact of the Spnb1 mutations, while resulting in 
statistically significant increases in Hb does not produce profound 
changes that could be viewed as a disease, however they may be 
associated with altered post-transfusion RBC lifespan. These murine 
models provide a tool to study the contribution of genetic change to 
donor variability in blood component storage and post-transfusion 
RBC survival that may be associated with transfusion outcomes. 
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